Today on the show, we introduced that the Food and Drug Administration has expanded its approval of CRISPR gene editing therapy. We are looking at the affordability of these treatments, which can cost millions of dollars. Plus, is bad marketing holding back health tech companies' growth? Learn more about how startups can up their game.
First, this week's World Economic Forum in Davos, Switzerland, had 32 events dedicated to AI. When they weren't comparing private jets, corporate executives were busy asking, “How can we make money with AI?” Marketplaces' Lily Jamali is joined by Christina Farr, health tech investor at OMERS Ventures, to share her perspective on these stories.
Learn more about everything we talked about
“AI is making waves at Davos, but CEOs are struggling to figure out how to make it pay.” (Reuters)
“AI fears creep into finance, business and law” from The Washington Post
“90% of CEOs are waiting for GenAI to rise above the hype or experiment in small ways” from Boston Consulting Group
“FDA Expands Use of Newly Approved CRISPR Therapies” on Axios
“U.S. FDA approves two gene therapies for sickle cell disease” from Reuters
“CRISPR pioneer Doudna envisions eradicating asthma and improving the climate” (From Marketplace Tech)
“Marketing is destroying digital health” (from Second Opinion)
“Amazon launches health monitoring program, partners with Omada Health” from Yahoo Finance
